Search Results - "Volant, E."

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer by Poumeaud, F., Morisseau, M., Cabel, L., Gonçalves, A., Rivier, C., Trédan, O., Volant, E., Frenel, J.-S., Ladoire, S., Jacot, W., Jamelot, M., Foka Tichoue, H., Patsouris, A., Teixeira, L., Bidard, F.-C., Loirat, D., Brunet, M., Levy, C., Bailleux, C., Cabarrou, B., Deleuze, A., Uwer, L., Deluche, E., Grellety, T., Franchet, C., Fiteni, F., Bischoff, H., Vion, R., Pagliuca, M., Verret, B., Bécourt, S., Reverdy, T., de Nonneville, A., Dalenc, F.

“…Background Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates (ADCs):…”
Get full text

Comments on the working paper: evaluative criteria for Catholic health care facilities by Volant, E

Get more information